{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:28:41Z","timestamp":1792319321984,"version":"4.4.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The coexistence of active pulmonary tuberculosis (TB) and small cell lung cancer (SCLC) is an exceptionally rare clinical phenomenon, presenting significant diagnostic and therapeutic challenges due to overlapping symptoms, radiological findings, and drug interactions. We report the case of a 68-year-old male with a four-month diagnostic journey, involving persistent cough, exertional chest tightness, and multiple inconclusive bronchoscopic examinations. Active TB was confirmed via sputum smear tests identifying acid-fast bacilli, while SCLC was diagnosed later through a third bronchoscopy, supported by elevated progastrin-releasing peptide (ProGRP, 127.28 pg\/mL). The patient received a two-month course of anti-TB therapy before initiating four cycles of etoposide-cisplatin chemotherapy, followed by chest radiotherapy. Anti-TB treatment was intermittently paused during chemotherapy cycles to minimize drug interactions, and the patient completed 11 months of therapy. Follow-up imaging showed partial resolution of the left upper lung lesion, with normalized tumor markers (ProGRP: 66.20 pg\/mL). However, at 17 months, disease progression was noted with a metastatic lesion in the right lower lobe. This case underscores the complex interplay between TB-induced chronic inflammation and tumor progression, highlighting the need for early tumor marker testing, advanced imaging modalities such as PET-CT, and tailored therapeutic strategies. Multidisciplinary collaboration is critical for optimizing outcomes in such rare and challenging scenarios. Further research into the mechanistic links between TB and SCLC could improve early diagnosis, guide therapeutic decisions, and inform preventive strategies.<\/jats:p>","DOI":"10.3389\/fonc.2025.1564686","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:00:42Z","timestamp":1756987242000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Concurrent active pulmonary tuberculosis and small cell lung cancer: diagnostic challenges and therapeutic insights from a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Meiling","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijirm.2024.001","article-title":"Understanding the complexities of post-tuberculosis lung disease: Implications for global health","volume":"9","author":"Yadav","year":"2024","journal-title":"IP Indian J Immunol Respir Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-272","article-title":"Clinical characteristics and survival of patients concurrently diagnosed with lung cancer and active pulmonary tuberculosis","volume":"11","author":"Lee","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1186\/s12885-020-07622-6","article-title":"The effect of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active tuberculosis: a retrospective analysis","volume":"20","author":"Chai","year":"2020","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.21037\/atm-20-5964","article-title":"Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis","volume":"8","author":"Ye","year":"2020","journal-title":"Ann Transl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1186\/s12885-018-4889-1","article-title":"Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study","volume":"18","author":"Hirashima","year":"2018","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"873\u201377","DOI":"10.3969\/j.issn.1000-8179.2018.17.542","article-title":"Retrospective clinical analysis of 298 cases of lung cancer complicated with pulmonary tuberculosis","volume":"45","author":"Yu","year":"2018","journal-title":"Chin J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"271\u201374","DOI":"10.3877\/cma.j.issn.1674-6902.2018.03.003","article-title":"Clinical characteristics of lung cancer complcated with pulmonary tuberculosis","volume":"11","author":"Zhang","year":"2018","journal-title":"Chin J Lung Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1017\/s0950268822000176","article-title":"Comparison of clinical and imaging features between pulmonary tuberculosis complicated with lung cancer and simple pulmonary tuberculosis: a systematic review and meta-analysis","volume":"150","author":"Sun","year":"2022","journal-title":"Epidemiol Infect"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8570212","article-title":"Squamous cell carcinoma in the post tuberculosis lung after 30 years of treatment completion","volume":"2020","author":"Arulanantham","year":"2020","journal-title":"Case Rep Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1583167","article-title":"Management and surgical outcomes of concurrent tuberculosis and lung cancer","volume":"65","author":"Evman","year":"2017","journal-title":"Thorac Cardiovasc Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7078652","article-title":"The value of adenosine deaminase 2 in the detection of tuberculous pleural effusion: A meta-analysis and systematic review","volume":"2022","author":"Zeng","year":"2022","journal-title":"Can Respir J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.52225\/narra.v3i2.135","article-title":"Coexistence of pulmonary tuberculosis and small cell lung carcinoma: A significant problem in tuberculosis-endemic country","volume":"3","author":"Arliny","year":"2023","journal-title":"Narra J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-004-0394-4","article-title":"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer","volume":"9","author":"Yonemori","year":"2004","journal-title":"Int J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"860-62","DOI":"10.3760\/cma.i.issn.1001-0939.2011.11.022","article-title":"A Case of small cell lung cancer combined with pulmonary and bronchial tuberculosis","volume":"34","author":"Kaishu","year":"2011","journal-title":"Chin J Tuberc Respir Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3892\/ol.2024.14627","article-title":"Challenges in the differential diagnosis of pulmonary tuberculosis vs","volume":"28","author":"Luo","year":"2024","journal-title":"Lung cancer: A Case Rep Oncol Lett"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/150306","article-title":"Significance of detecting the levels of miR-29a, survivin and interferon gamma release assay in patients with lung cancer and tuberculosis","volume":"31","author":"Sun","year":"2022","journal-title":"Adv Clin Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7860\/jcdr\/2021\/48674.15213","article-title":"Uncommon high resolution computed tomography features of pulmonary tuberculosis: A case series","volume":"15","author":"Swarna","year":"2021","journal-title":"J Clin Diagn Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-019-01040-w","article-title":"How radiology can help pulmonary tuberculosis diagnosis: analysis of 49 patients","volume":"124","author":"Carlesi","year":"2019","journal-title":"Radiol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5152\/dir.2020.20051","article-title":"Safety and diagnostic accuracy of percutaneous CT-guided transthoracic biopsy of small lung nodules (\u226420 mm) adjacent to the pericardium or great vessels","volume":"27","author":"Chen","year":"2021","journal-title":"Diagn Interv Radiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.20.22780","article-title":"Diagnostic accuracy of CT-guided core needle biopsy for thin-walled cavitary pulmonary lesions","volume":"216","author":"Shin","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2012.09.008","article-title":"CT-guided percutaneous core needle biopsy for small (\u226420 mm) pulmonary lesions","volume":"68","author":"Li","year":"2013","journal-title":"Clin Radiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"00273-19","DOI":"10.1128\/aac.00273-19","article-title":"The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH","volume":"63","author":"Iacobino","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01124-13","article-title":"Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine","volume":"57","author":"Williamson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00683-23","article-title":"Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis","volume":"67","author":"Stemkens","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225020-00005","article-title":"Clinically significant interactions with drugs used in the treatment of tuberculosis","volume":"25","author":"Yew","year":"2002","journal-title":"Drug Safety"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.24-0248","article-title":"Key factors influencing liver function injury in elderly patients with newly diagnosed pulmonary tuberculosis complicated by diabetes after antituberculosis treatment","volume":"112","author":"Ma","year":"2025","journal-title":"Am J Trop Med Hyg"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10135","DOI":"10.1038\/s41598-023-35930-x","article-title":"Proteomic-based identification of APCS as candidate protein for diagnosis of patients exhibiting anti-tubercular drug induced liver injury","volume":"13","author":"Kaur","year":"2023","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.61920\/jddb.v1i01.16","article-title":"Hepatotoxicity induced by anti-tuberculosis medications: exploring causes, risk factors, and potential mitigation strategies","author":"Zade","year":"2023","journal-title":"J Drug Delivery Biotherapeutics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.05.030","article-title":"Management of co-existent tuberculosis and lung cancer","volume":"122","author":"Ho","year":"2018","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6811-20","article-title":"Safe concurrent use of anti-tuberculosis drugs and pembrolizumab in a patient with non-small-cell lung cancer who was infected with mycobacterium tuberculosis","volume":"61","author":"Nakahama","year":"2022","journal-title":"Intern Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.32","article-title":"Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control","volume":"28","author":"Nalbandian","year":"2009","journal-title":"Oncogene"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.26693\/jmbs06.03.065","article-title":"Tuberculosis and lung cancer: features of carcinogenesis","author":"Filenko","year":"2021","journal-title":"Ukra\u00efns\u2032kij \u017eurnal medicini b\u00ecolog\u00ec\u00ef ta sportu"},{"key":"B34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.21926\/obm.genet.2302183","article-title":"Mycobacterium tubercular mediated inflammation and lung carcinogenesis: connecting links","volume":"7","author":"Vashishth","year":"2023","journal-title":"OBM Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1590\/s1806-37132008001100009","article-title":"Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis","volume":"34","author":"Peresi","year":"2008","journal-title":"J Bras Pneumol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11846","article-title":"A comprehensive review of chemokine CXC17 (VCC1) in cancer, infection, and inflammation","volume":"46","author":"Gowhari Shabgah","year":"2022","journal-title":"Cell Biol Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/387014","article-title":"DNA damage in inflammation-related carcinogenesis and cancer stem cells","volume":"2013","author":"Ohnishi","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/1040841x.2016.1185603","article-title":"T-cell exhaustion in tuberculosis: pitfalls and prospects","volume":"43","author":"Khan","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660916","article-title":"Host-directed therapies: modulating inflammation to treat tuberculosis","volume":"12","author":"Krug","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01456-22","article-title":"TREM2 promotes immune evasion by mycobacterium tuberculosis in human macrophages","volume":"13","author":"Dabla","year":"2022","journal-title":"mBio"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.celrep.2019.04.072","article-title":"VEGF-A from granuloma macrophages regulates granulomatous inflammation by a non-angiogenic pathway during mycobacterial infection","volume":"27","author":"Harding","year":"2019","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3760\/CMA.J.ISSN.1673-422X.2015.03.009","article-title":"Epigenetic modifications and non-small cell lung cancer","volume":"42","author":"Zhao","year":"2015","journal-title":"J Int Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.12.001","article-title":"Local targeting NF-\u03baB in the lung tissue of TB-infected mice diminishes the level of pathology","volume":"103","author":"Shepelkova","year":"2017","journal-title":"Tuberculosis (Edinb)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30220","article-title":"Mycobacterium tuberculosis glycolipoprotein LprG inhibits inflammation through NF-\u03baB signaling of ERK1\/2 and JNK in LPS-induced murine macrophage cells","volume":"123","author":"Abekura","year":"2022","journal-title":"J Cell Biochem"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3390\/ijerph20021282","article-title":"The bidirectional relationship between pulmonary tuberculosis and lung cancer","volume":"20","author":"Preda","year":"2023","journal-title":"Int J Environ Res Public Health"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1564686\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T12:00:46Z","timestamp":1756987246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1564686\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":45,"alternative-id":["10.3389\/fonc.2025.1564686"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1564686","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"article-number":"1564686"}}